Myopia Profile


Learning more about Essilor Stellest

Posted on May 15th 2023 by Jeanne Saw

Sponsored by


In this article:

Essilor Stellest lenses have been shown to effectively reduce the rate of myopic progression. Here's an in-depth dive into the evidence.

Essilor® Stellest® is part of the newest generation of myopia controlling spectacle lens technologies and has become a robust choice for correcting and controlling myopia. There's a lot we already know about the lenses - you can read about it in our article Understanding The New Essilor Stellest Spectacle Lens - but what are we still learning? This article will go through the newest research coming out regarding the Essilor® Stellest® lenses.

Essilor Stellest and Visual Fields

The Essilor® Stellest® lenses are made up of 11 rings of 1021 contiguous aspherical lenslets that surround a central clear zone of 9mm.1,2 While they do not appear to have any impact on visual acuity1 and accommodation3 and minimal impacts on contrast sensitivity and glare sensitivity,4 the potential impact on visual field sensitivity has only recently been studied.

In November 2022, Gao et al published findings regarding the impacts of spectacles with highly aspherical lenslets on visual sensitivity using automated static perimetry. The study included 21 adults aged 26 to 61 years old with spherical equivalent refractive error (SER) ranging from +0.88D to -8.75D. Participants were asked to complete visual fielding testing using a Goldmann perimeter, and targets were presented within 30°eccentricity. The visual field sensitivity was obtained through one lens with highly aspherical lenslets (HAL), and one single vision lens and compared.

It was found that there was no significant difference between visual field sensitivity as measured through single vision lenses and HAL lenses, indicating that there is no measurable impact on visual field sensitivity, after accounting for age and SER.5

Essilor Stellest BHVI Cross-over Trial

A cross-over clinical trial is a research method where individuals undergo a series of treatments, rather than being assigned into a control group or treatment group. This way, participants in a cross-over clinical trial act as their own comparison group. This trial design allows researchers to assess and compare the effects of different treatments within each participant and is valuable for studying long-lasting conditions or interventions with sustained impacts.6

The Brien Holden Vision Institute (BHVI) conducted a cross-over trial comparing HAL lenses and single vision lenses.7 Stage 1 of the trial involved 119 Vietnamese children aged 7 to 13 years old with SER range of -0.75 to -4.75D who were given HAL or single vision lenses to be worn for 6 months. In stage 2, these lenses were switched from HAL to single vision and vice versa and again worn for another 6 months. After stage 2, all children were switched to HAL lenses. 


Figure 1 from open access paper Spectacle Lenses With Highly Aspherical Lenslets for Slowing Myopia: A Randomized, Double-Blind, Cross-Over Clinical Trial7 with the following caption: “Observed changes in spherical equivalent refractive error and axial length for participants who completed all stages.”

Results indicate that HAL lenses slowed myopia compared to single vision lenses, and that this was evident between groups wearing different lenses, and at the individual level when lenses were switched to HAL lenses. The research further indicates that there is no rebound effect when switching from HAL to single vision lenses.7

Essilor Stellest 3-year and 4-year data

The one-year and two-year randomized control trial data established the Essilor® Stellest® lenses as an efficacious myopia control treatment option on par with the current 'best' interventions of orthokeratology, dual-focus soft contact lenses and 0.05% atropine.1-2,8

The 3-year data is a continuation of the original randomized control trial.9 The study participants were separated into groups:

  • HAL1 group: 52 children who have been wearing HAL lenses for 2 years continue to wear HAL lenses
  • HAL2 and HAL3 groups: children who had been wearing single vision lenses (n=48) or slightly aspherical lenslets (SAL) lenses (n=51) are switched to HAL lenses.
  • nSVL group: 56 children with no prior history of myopia control were newly recruited at the start of the 3 year trial extension date and were given single vision lenses only. These children were matched for age, sex, cycloplegic SER and axial length to the HAL3 group.

It was found that the HAL1 group benefited from less myopia progression and axial elongation compared to single vision over 3 years. In the HAL2 and HAL3 groups, they also benefited from slowed myopia progression and axial elongation after switching to HAL lenses after 2 years of wearing single vision lenses or SAL lenses. In fact, No differences among the three HAL treatment groups were found in this third extension year. The nSVL group was compared as a control against the third year changes of the HAL groups, and it was found that there was significantly more axial elongation and SER progression in the nSVL group compared to all 3 HAL groups.9

Early reports from the 4-year clinical trial data indicate positive results. 43 children completed the 4th year follow-up and were now 11- to 16-year-olds with an average SER of -3.70±1.22 D and AL of 25.28±0.84 mm. Data was compared to single vision lens models based on data from the first 2 years of the clinical trial: it was found that myopia progression and axial elongation was slower in children wearing HAL than in the modeled single vision control group even in the fourth year of wear.10

Final thoughts

The current research further indicates that the Essilor® Stellest® lenses are not only highly effective in slowing the progression of myopia, but do not impact visual function even when it comes to visual field sensitivity. It remains a worthy weapon in the myopia management armory, as long as compliance to full-time wear is emphasized.

Meet the Authors:

About Jeanne Saw

Jeanne is a clinical optometrist based in Sydney, Australia. She has worked as a research assistant with leading vision scientists, and has a keen interest in myopia control and professional education.

As Manager, Professional Affairs and Partnerships, Jeanne works closely with Dr Kate Gifford in developing content and strategy across Myopia Profile's platforms, and in working with industry partners. Jeanne also writes for the CLINICAL domain of, and the My Kids Vision website, our public awareness platform. 

This content is brought to you thanks to unrestricted educational grant from


Back to all articles

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.